Dinar capsules contain 300 mg cefdinir.
Contains the active ingredient cefdinir, an extended-spectrum, semisynthetic third generation cephalosporin, for oral administration.
Bactericidal activity of cefdinir results from inhibition of cell wall synthesis .Cefdinir has been shown to be active against most strains of the following microorganisms .Aerobic gram –positive microorganisms as staphylococcus aureus (including B lactamase producing strain ) ,streptococcus pneumoniae ,streptococcus pyogenes.Aerobic gram – negative microorganisms as haemophilus influenzae ,haemophilus parainfluenzae ,moraxella catarrhalis (including B lactamase producing strain ) .
1-Community acquired pneumonia.
2-Acute exacerbations of chronic bronchitis.
3-Acute maxillary sinusitis.
4-Pharyngitis/ Tonsillitis caused by streptococcus pyogenes.
5-Uncomplicated skin and skin structure infections caused by staphylococcus aureus and streptococcus pyogenes.
Adults: 300 mg twice daily or 600 mg once daily for 10 days.
-Dosing adjustment in renal impairment: CLcr<30 ml/minute: 300 mg once daily.
Haemodialysis removes cefdinir: recommended initial dose: 300 mg every other day. At the conclusion of each haemodialysis session, 300 mg should be given.
In patients with known allergy to the cephalosporin class of antibiotics.
Box contains 10 capsules in 1 strip.